Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
Outlook Therapeutics completes enrollment for NORSE EIGHT trial, evaluating ONS-5010 in wet AMD patients. NORSE EIGHT, under an FDA SPA, is the final trial before resubmitting the BLA for ONS-5010. Topline results expected in Q4 CY2024, with BLA resubmission planned for Q1 CY2025.
Related Clinical Trials
Reference News
Outlook Therapeutics completes enrollment for NORSE EIGHT trial, evaluating ONS-5010 in wet AMD patients. NORSE EIGHT, under an FDA SPA, is the final trial before resubmitting the BLA for ONS-5010. Topline results expected in Q4 CY2024, with BLA resubmission planned for Q1 CY2025.
Outlook Therapeutics completes enrollment for NORSE EIGHT trial, evaluating ONS-5010 in wet AMD patients, with topline results expected in Q4 CY2024 and BLA resubmission planned for Q1 CY2025.